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Abstract 
Objectives: Malignant pleural mesothelioma (MPM) is an aggressive tumor with a poor 
prognosis. microRNA-34b/c (miR-34b/c), which plays an important role in the 
pathogenesis of MPM, is frequently downregulated by DNA methylation in 
approximately 90% of MPM cases.  In this study, we estimated the degree of 
miR-34b/c methylation in serum-circulating DNA using a digital methylation specific 
PCR assay (MSP). 
Materials and Methods: A real-time MSP assay was performed using the SYBR Green 
method.  The melting temperature (Tm) of each PCR product was examined using a 
melting curve analysis.  For a digital MSP assay, 40 wells were analyzed per sample.  
A total of 110 serum samples from 48 MPM cases, 21 benign asbestos pleurisy (BAP) 
cases, and 41 healthy volunteers (HVs) were examined.   
Results: Positive range of Tm value for miR-34b/c methylation was defined as 77.71 °C 
to 78.79 °C which was the mean ± 3 standard deviations of 40 wells of a positive 
control.  The number of miR-34b/c methylated wells was counted per sample 
according to this criterion.  The number of miR-34b/c methylated wells in MPM cases 
was significantly higher than that in BAP cases (P = 0.03) or HVs (P < 0.001).  
Advanced MPM cases tended to have higher number of miR-34b/c methylated wells 
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than early MPM cases.  Receiver–operating characteristic (ROC) curve analysis 
revealed that three number of miR-34b/c methylated wells per sample was the best 
cut-off of positivity of MPM with a 67% of sensitivity and a 77% specificity for 
prediction.  The area under the ROC curve was 0.77.  
Conclusions: Our digital MSP assay can quantify miR-34b/c methylation in 
serum-circulating DNA.  The degree of miR-34b/c methylation in serum-circulating 
DNA is associated with MPM, suggesting that this approach might be useful for the 
establishment of a new detection system for MPM. 
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1. Introduction 
Asbestos exposure has been reported to cause asbestos-related diseases such as 
malignant pleural mesothelioma (MPM), primary lung cancer, and benign asbestos 
pleurisy (BAP) [1].  Although the use of asbestos has been strictly restricted, the 
number of MPM patients who had been expoed to asbestos is still increasing [2, 3].  
MPM is an aggressive tumor with a dismal prognosis, with a median overall survival 
period of 12 months [2].  Approximately 85% – 90% of patients with MPM present 
with unresectable disease at the time of diagnosis [4].  Additionally, both MPM and 
BAP cases suffer from common symptoms caused by pleural effusion.  These 
conditions are difficult to distinguish using not only radiological imaging tests such as 
chest X-ray and computed tomography, but also cytological examinations of pleural 
effusion [5, 6].  Therefore, pathological validation by means of an invasive pleural 
biopsy with a full-layer resection of the parietal pleura is strongly recommended [7], 
although the possibility of a sampling error at the time of biopsy is significant; whether 
a few pieces of the parietal pleura are actually representative of the entire pleural lesion 
is unclear [8].  Considering the difficulty associated with the pathological diagnosis of 
MPM, a definitive diagnosis based on pathological finding alone is occasionally 
challenging [9, 10].  Since misguided diagnoses lead to delays in treatment and early 
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diagnosis and subsequent treatment are thought to improve the clinical outcome of 
patients with MPM, a critical need exists for the development of a reliable and 
non-invasive test for the detection of MPM. 
Reportedly, the downregulation of several tumor suppressive genes, such as 
BMP3b [11], BMP6 [11], IGFBP [12], and RASSF1A [13], frequently occurrs as a result 
of DNA methylation in MPM cases.  Similar to protein coding genes, microRNAs 
(miRs), which are a group of non-coding small RNAs that mostly regulate their target 
messenger-RNAs through posttranscriptional repression [14], are downregulated 
through the methylation of their promoter regions [15].  In fact, we have recently 
revealed that miR-34b/c, which plays an important role in the pathogenesis of MPM, is 
downregulated by promoter methylation in approximately 90% of MPM cases [16]. 
Blood examinations are less-invasive diagnostic methods and several serum 
biomarkers such as mesothelin, osteopontin, CYFRA21-1, and Fibulin-3 have been 
reported for the diagnosis of MPM [10, 17-19].  Among them, mesothelin has been 
well-studied and is currently considered to be the best serum biomarker of MPM 
available, although a recent systematic review of medical literature revealed a limited 
sensitivity [20].  The presence of nucleic acids in the blood was recognized more than 
30 years ago [21].  Solid malignant tumors are known to release a significant amount 
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of genomic DNA into the systemic circulation probably through cellular necrosis and 
apoptosis [21, 22].  Therefore, cell-free circulating DNA in the serum or plasma is 
considered to be a source of useful biomarker during carcinogenesis [23, 24], although 
tumor-derived circulating DNAs are fragmented and present in the blood flow amidst a 
high background of normal cell-derived DNAs [22, 25].  Highly sensitive assays are 
required to detect tumor-specific genetic alterations in serum-circulating DNAs in 
patients with malignant tumors [23]. 
Digital PCR assays have been developed as a highly sensitive assay for the 
detection of rare genetic abnormalities amidst a high normal background.  Digital PCR 
was originally developed as a tool for the amplification of individual molecules for 
purposes of identifying and counting individual DNA molecule sequence alterations[26], 
and now is applied to determine coding mutations, loss of heterozygosity, allelic 
imbalance and SNP polymorphisms [27, 28].  This principle has been also applied to 
DNA methylation analyses [29].  One of advantages of digital PCR is the sequestration 
of competing background molecules into negative wells that do not participate in the 
PCR amplification, leading to improve the ratio of template-to-background in the 
positive wells [29]. Particularly, competition for primer annealing by background DNA 
is a major problem in the detection of low-abundance methylation variants by MSP, 
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because sequence redundancy is increased in bisulfite converted DNA, which contains 
only three bases outside of sites of DNA methylation [29].  To the best of our 
knowledge, the digital PCR assay for the detection of methylation of miR genes has 
never been applied as a blood detection test for MPM. 
To establish a new detection system for MPM, we developed a digital MSP 
assay to evaluate the degree of miR-34b/c methylation in serum-circulating DNAs in 
patients with MPM, comparing those in patients with BAP, and healthy volunteers 
(HVs). 
 
2. Material and methods 
2.1. Sample collection 
We obtained more than 2 mL of peripheral blood samples from 48 MPM cases, 
21 BAP cases, and 41 HVs at Okayama University Hospital, Okayama Rosai Hospital, 
and the National Hospital Organization Yamaguchi Ube Medical Center between 
August 2006 and August 2011.  The characteristics of all 110 cases are shown in Table 
1.  The blood samples were centrifuged at 3500 rpm for 5 min within one hour after 
the collection, and the sera were collected and stored in aliquots at -80 °C at each 
institute until further experiments.  As a positive control (POC), the supernatant of a 
culture medium for NCI-H290 (H290), an MPM cell line harboring heavy methylation 
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of miR-34b/c [16], was collected and stored at -80 °C.  We also collected the 
supernatant of culture medium for LP9, a non-malignant peritoneal mesothelial cell line, 
as a negative control.  H290 was a kind gift from Dr. Adi F. Gazdar (Hamon Center for 
Therapeutic Oncology Research and Department of Pathology, University of Texas 
Southwestern Medical Center at Dallas, Dallas, TX).  We purchased LP9 from the 
Coriell Cell Repository (Camden, NJ).  Informed consent was obtained from each case 
at each institute.  The study was approved by the ethics committee of Okayama 
University (approval number for the genome study, 173).  
 
2.2. DNA extraction and bisulfite conversion 
We extracted DNA from 1 mL of serum sample or supernatant of cell culture 
medium using the QIAamp Circulating Nucleic Acid Kit (Qiagen, Carlsbad, CA), 
according to the manufacturer’s recommendations, and eluted the DNA in 120 μL of the 
kit’s elution buffer.  The DNA concentration was quantified using NanoDrop ND-1000 
(NanoDrop Technologies, Wilmington, DE) and the mean dosage of the extracted serum 
DNA was 4.8 ± 1.8 μg (40 ± 15 ng/μL).  Among the 120 μL of extracted serum DNA, 
20 μL of DNA (0.8 ± 0.3 μg) was used for bisulfite conversion using the Epitect 
Bisulfite Kit (Qiagen) and the DNA was eluted in 40 μL of the kit’s elution buffer and 
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used as the templates for the assays described below.  As for the H290 and LP9 cell 
lines, the concentrations of extracted DNA from the supernatant of cell culture medium 
were adjusted to 40 ng/μL.  Twenty microliters (0.8 μg) were applied for bisulfite 
conversion using Epitect Bisulfite Kits (Qiagen) with 40 μL of the final elution. 
 
2.3. Real-time methylation specific PCR (MSP) assay 
We designed three sets of MSP primers for the predicted bisulfite-modified 
sequences based on the nucleotide sequence submitted to GenBank (gene accession 
numbers, NR_029839 for miR-34b and NR_035765 for miR-34c) and our previous 
report [16].  Among them, we decided to use the following primer set because of its 
high sensitivity (data not shown): forward primer, CGTACGGGGTCGAGAGAGT; 
reverse primer, CTCGACCCGAACTCCCACT.  The length of the PCR product was 
83 bp.  A real-time MSP assay was performed using the StepOnePlus™ Real-Time 
PCR System (Applied Biosystems) in a final volume of 20 L per well containing 1 L 
of bisulfited DNA (20 ± 7.5 ng/well for serum and 20 ng/well for cell supernatant), 10 
μL of 2 x Power SYBR® Green PCR Master Mix (Applied Biosystems), and 0.3 μL of 
both 10 μM forward and reverse primers.  The PCR conditions were as follows: an 
initial denaturation step at 95 °C for 10 min, followed by 50 cycles of 94 °C for 15 
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seconds and 60 °C for 60 seconds.  After PCR amplification, the melting temperature 
(Tm) of each PCR product was examined using a melting curve analysis.   
 
2.4. Statistical analysis 
Differences in the number of miR-34b/c methylated wells were compared 
between two categorized groups using the Mann-Whitney test.  P values less than 0.05 
were considered statistically significant.  The receiver–operating characteristic (ROC) 
curve analysis was performed to determine the cut-off point for the number of 
miR-34b/c methylated wells.  P values less than 0.05 were considered statistically 
significant. 
 
3. Results 
3.1. Detection of positive wells containing miR-34b/c methylated DNA using a melting 
curve analysis  
The fluorescent signal after PCR amplification was detected in all the wells, 
including those containing a water blank, because of nonspecific PCR reactions.  To 
detect the positive wells containing miR-34b/c methylated DNA, we defined the 
positive range of the Tm value for miR-34b/c methylation.  We investigated the Tm 
values of 40 wells of the POC samples, 40 wells of LP9 supernatant samples (negative 
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control), and 40 wells containing a water blank.  The supernatants of the culture 
medium for the cell lines contained cell-derived DNA from apoptotic cells and were 
used as models of the serum samples.  The range of the Tm values differed between 
the 40 POC wells (mean ± standard deviation [SD], 78.25 °C ± 0.18 °C) and the 40 
water blank wells (75.01 °C ± 0.47 °C) (Figure 1).  In addition, the length of the PCR 
product of the water blank was confirmed to be shorter than that of POC using gel 
electrophoresis (Supplemental Figure 1).  Furthermore, the Tm values of 39 out of 40 
of the wells of the LP9 supernatant sample (negative control) were within the range of 
the WB samples (Figure 1).  We confirmed that none of the CpG sites that our MSP 
assay could detect were methylated in the LP9 cell lines using bisulfite sequencing (data 
not shown).  According to this result, we defined the positive range of the Tm values 
for miR-34b/c methylated wells as 77.71 °C to 78.79 °C, which was within the mean 
Tm values ± 3 SDs of 40 wells of the POC samples.  
 
3.2. Digital MSP assay for miR-34b/c methylation 
In the preliminary study, we examined miR-34b/c methylation in 1 L of 
bisulfited DNA from serum-circulating DNA using a real-time MSP assay (one well per 
sample).  miR-34b/c methylation was not present in 1 L of bisulfited DNA from 
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serum-circulating DNA from the MPM cases, even though the primary tumor harbored 
heavy miR-34b/c methylation.  Considering the dilution effect of tumor-derived DNA 
in serum-circulating DNA, we repeated the real-time MSP assay for the same 
serum-circulating DNA and found that miR-34b/c methylation could occasionally be 
detected.  Based on these findings, we decided to perform a real-time MSP assay for 
40 PCR wells per serum-circulating DNA sample using the whole elution of bisulfited 
DNA (40 L).  The quantification of miR-34b/c methylation was performed using a 
digital MSP assay by counting the number of miR-34b/c methylated wells per sample.  
For this purpose, a total of 800 μL of PCR mixture containing 40 μL bisulfited DNA 
templates were first made, and we then distributed them in 20-L aliquots per well for a 
total of 40 wells.  After PCR amplification, the Tm value of each PCR product was 
calculated using a melting curve analysis, and the miR-34b/c methylation status of each 
PCR well was classified according to the positive range of the Tm values for miR-34b/c 
methylation.  In every experiment, a POC sample was placed into a 96-well 
polypropylene PCR plate to confirm that the Tm value of the POC sample fell within 
the positive range for miR-34b/c methylation. 
 
3.3. Quantification of miR-34b/c methylation using a digital PCR assay 
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A distribution map showing the Tm values for all the wells in all the cases was 
shown in Figure 1.  Each group showed a characteristic distribution of Tm values.  
Biphasic peaks of Tm values were seen for the MPM and BAP cases, in which the low- 
and high-grade Tm values were comparable to those of the water blank (low-grade) and 
the POC of miR-34b/c methylation (high-grade), respectively.  The Tm values of the 
HVs were mainly around that of the water blank.  
The numbers of miR-34b/c methylated wells in the MPM cases was 
significantly higher than those in the BAP cases (P = 0.03) or the HVs (P < 0.001) 
(Figure 2).  The BAP cases also had significantly higher numbers of miR-34b/c 
methylated wells than the HVs (P = 0.01). 
 
3.4. Association between the numbers of miR-34b/c methylated wells and patient 
characteristics 
We evaluated the association between the numbers of miR-34b/c methylated 
wells per sample and clinicopathological factors.  No significant differences in the 
numbers of miR-34b/c methylated wells were seen when compared according to age, 
sex, smoking status, and histological subtype.  MPM cases with an advanced clinical 
stage tended to exhibit higher numbers of miR-34b/c methylated wells than those with 
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an early clinical stage except in two cases (Supplemental Figure 2).  These two MPM 
cases with clinical stage I had over 20 miR-34b/c methylated wells; one of the patients 
had 34 miR-34b/c methylated wells, while the other had 22 miR-34b/c methylated wells 
and he suffered from a rapid increase in the thickness of the pleura immediately after 
the initial diagnosis and collection of the serum sample, although the patient was 
subsequently lost to follow-up. 
 
3.5. Optimal cut-off point for miR-34b/c methylation by ROC curve analysis 
In order to determine the cut-off number of miR-34b/c methylated wells for 
MPM cases, we carried out ROC curve analysis comparing MPM cases versus other 
non-malignant cases (Figure 3 and Supplemental table 1).  According the ROC curve 
for all cases, three number of methylated wells was the best cut-off of positivity of 
MPM with a 67% of sensitivity and a 77% specificity for prediction.  The area under 
the ROC curve (AUC) was 0.77.   
 
4. Discussion 
In this study, we established a highly sensitive assay for the quantification of 
miR-34b/c methylation in serum-circulating DNA to distinguish MPM cases from BAP 
cases or HVs.  Our assay showed that the degree of miR-34b/c methylation was 
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significantly higher in serum-circulating DNA from MPM cases than from BAP cases or 
HVs.  MPM cases with an advanced clinical stage tend to have more miR-34b/c 
methylated wells than those with early stage disease, although two early-stage MPM 
cases did show heavy miR-34b/c methylation of their serum-circulating DNAs. 
The dosage of DNA in the blood circulation itself is associated with tumor 
progression in patients with malignant tumors [30].  Needless to say, the degree of 
tumor-specific alterations in serum-circulating DNA can be considered a more specific 
marker for the detection of malignant tumors than the amount of total serum-circulating 
DNA.  PCR reactions for the detection of these tumor-specific alterations in 
serum-circulating DNA can be interrupted not only by the fragmentation of DNA 
derived from tumor cells, but also by a high background of DNA derived from 
non-malignant cells.  To overcome these difficulties, several sensitive assays have been 
developed [29, 31, 32] .  Among them, digital PCR has been established as a highly 
sensitive assay for the detection of minor genetic alterations among a vast number of 
normal alleles [27, 29].  Digital PCR can also calculate the dosage of the genetic 
alteration in a sample by determining the percentage of PCR wells with a positive 
reaction [29], with more precise quantification enabled by analysis of more PCR wells 
per sample.  Of note, although we used TaqMan-based real-time PCR assays in our 
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preliminary experiment, its sensitivity was low and we finally selected the present 
method (data not shown).  
Our results showed that more than three miR-34b/c methylated wells yielded 
the highest discriminative ability with a 67% sensitivity and a 77% specificity for 
predicting the presence of MPM.  The AUC was 0.77, indicating that the established 
assay had a moderate diagnostic accuracy for predicting the occurrence of MPM [33, 
34] .  As a positive test, a high specific threshold is typically required, and if we opt for 
a specificity of 95% (ie, a false-positive rate of one out of 20), a sensitivity of our assay 
results in 38%.  For a negative test result to aid in excluding diagnosis, a high sensitive 
threshold is generally required.  At a selected sensitivity of 95%, the specificity of this 
assay was 24%.  These results suggested that the sensitivity and specificity of our 
assay is almost similar to those of serum mesothelin level in an individual patient data 
meta-analysis (AUC = 0.77, a sensitivity of 32% at 95% specificity) [20].  With regard 
to our sensitive assay, false positive cases are present in 43% of BAP cases and 12% of 
HVs using a cut-off value of three methylated wells.  Further investigation is 
warranted for improvement of both sensitivity and specificity by combining with other 
biomarkers.  
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Two early-stage MPM cases exhibited heavy miR-34b/c methylation, 
indicating that our sensitive assay might detect miR-34b/c methylation during the early 
stage of MPM pathogenesis.  Obviously, the limitation of clinical staging based on 
conventional radiological examinations should be considered, since one case 
experienced the rapid progression of the MPM soon after the initial diagnosis.  The 
serum level of miR-34b/c methylation might reflect biological malignancy much more 
accurately than clinical staging.  Further investigations of large-scaled studies are 
needed to clarify this issue.  The sequential occurrence of other malignant tumors is 
another consideration, since miR34-b/c methylation can be observed in patients with 
other malignant tumors, such as lung [35, 36], colorectal [15], and gastric cancers [37].  
Regarding this issue, these malignant tumors were not obviously coincidental in any 
case of this study.  
In conclusion, our digital MSP assay can quantify miR-34b/c methylation in 
serum-circulating DNA, revealing that miR-34b/c methylation is more heavily and 
frequently present in serum-circulating DNA from MPM cases than from BAP cases or 
HVs.  This approach might be useful for the establishment of a new detection system 
for MPM. 
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